Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of metformin to reversion of cisplatin resistance of ovarian cancer

A metformin and ovarian cancer technology, applied in the new medical application of metformin, the application field of metformin in reversing cisplatin resistance in ovarian cancer, can solve the problems that plague the treatment of ovarian cancer

Inactive Publication Date: 2018-11-23
THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Chemotherapy resistance is the main cause of patient death and a major problem in the treatment of ovarian cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of metformin to reversion of cisplatin resistance of ovarian cancer
  • Application of metformin to reversion of cisplatin resistance of ovarian cancer
  • Application of metformin to reversion of cisplatin resistance of ovarian cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Example 1. Metformin inhibits the proliferation of cisplatin-resistant ovarian cancer cells in vitro

[0026] (1) Detection of the effect of different concentrations of metformin on the proliferation of cisplatin-resistant ovarian cancer cell lines

[0027] Cisplatin-resistant ovarian cancer cell lines CP70 and C13K were divided into 8×10 3 / hole and 1×10 4 The concentration per well was inoculated in a 96-well plate for 24 hours (i.e. after 24 hours of cell starvation, the medium was DMEM / F12, purchased from sigma, catalog number D6241), and replaced with metformin containing different concentrations (purchased from sigma, catalog number No. D150969-5G) complete medium (with no metformin as the control, metformin concentrations were set to 0.01mmol / L, 0.1mmol / L, 1mmol / L and 10mmol / L), after 48 hours with BrdU-ELISA reagent Roche (Cell Proliferation ELISA, BrdU (colorimetric) Cat. No. 11647229001) was used to detect changes in the proliferation of each cell (prolifera...

Embodiment 2

[0032] Example 2. Metformin promotes apoptosis of cisplatin-resistant ovarian cancer cell lines

[0033] Use AnnexinV / PI kit (purchased from Invitrogen Company) to detect by flow cytometry, after obtaining different concentrations of metformin treatment (cultivation method is the same as in Example 1), the results are as follows: figure 2 As shown, it can be seen that the percentage of apoptosis of ovarian cancer drug-resistant cell lines (C13K and CP70) after metformin culture was significantly increased (lower right quadrant), and increased with the increase of metformin concentration.

Embodiment 3

[0034] Example 3. Metformin changes the cell cycle of cisplatin-resistant ovarian cancer cells

[0035] Different concentrations of metformin were used to culture ovarian cancer drug-resistant cell lines (C13K and CP70) for 24 hours (the culture method was the same as in Example 1), and then detected by flow cytometry, the results were as follows: figure 1 As shown, it can be seen that the proportion of cell cycle G1 phase is significantly increased, indicating that cell growth is retarded.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of metformin to reversion of cisplatin resistance of ovarian cancer. The metformin can be used for preparing drugs for preventing and / or treating the ovarian cancer. The metformin can also be used for preparing products with any of the following functions: 1) inhibiting the proliferation of ovarian cancer cells; 2) accelerating the apoptosis of the ovarian cancer cells; 3) delaying the growth of the ovarian cancer cells; and the ovarian cancer is resistant to cisplatin. The metformin is applied together with a chemotherapeutic drug, and the chemotherapeuticdrug is the cisplatin. The experimental result of a nude mice model with chemotherapy-resistant ovarian cancer (ovarian cancer cells are CP70 cells and C13K cells, and the chemotherapy drug is the cisplatin) shows that the metformin changes the growth of chemotherapy-resistant ovarian cancer cells by regulating cell cycle (delaying cell growth), accelerating cell apoptosis, inhibiting cell proliferation and the like. An in-vivo animal experiment shows that the metformin can effectively inhibit the growth rate of subcutaneous tumors in drug-resistant ovarian cancer animal models, and reverse the cisplatin resistance.

Description

technical field [0001] The invention relates to a new medical application of metformin, in particular to the application of metformin in reversing cisplatin drug resistance of ovarian cancer, and belongs to the field of medicine. Background technique [0002] Ovarian cancer is the third most common malignant tumor in the female reproductive system, and its case fatality rate ranks first. The current treatment is mainly the first cytoreductive surgery followed by platinum-based combined chemotherapy. 80% of the patients had a significant effect of the first chemotherapy, but most of the patients died due to chemotherapy resistance and relapse. The 5-year survival rate for ovarian cancer is only 30%. Chemotherapy resistance is the main cause of patient death, and it is also a major problem in the treatment of ovarian cancer. Therefore, finding a drug that can improve and reverse ovarian cancer chemotherapy resistance has become the key to the current treatment of ovarian can...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/155A61K33/24A61P35/00
CPCA61K31/155A61K33/24A61K2300/00
Inventor 谢娅廖秦平蔡蕾纪妹郭瑞霞赵倩陈锐胡倩刘亚楠付坤
Owner THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com